The AMA Urges Removing All Barriers to Treatment for Substance Use Disorder
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System

JAMA Psychiatry

Traci C. Green, PhD, MSc; Jennifer Clarke, MD; Lauren Brinkley-Rubinstein, PhD; Brandon D. L. Marshall, PhD; Nicole Alexander-Scott, MD, MPH; Rebecca Boss, MA; Josiah D. Rich, MD, MPH
Learn More
Public Policy Statement on the Regulation of Office-Based Opioid Treatment
Learn More
Why It’s Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy

AMA Journal of Ethics. September 2017, Volume 19, Number 9: 922-930.

Sarah E. Wakeman, MD

Learn More
A Primer on Antagonist-Based Treatment of Opioid Use Disorders in the Office Setting
Learn More
Preparation and Administration of Extended-Release Naltrexone
Learn More
XR-Naltrexone: A Step-by-Step Guide

Created by Adam Bisaga, MD

Learn More
Providers’ Clinical Support System For Medication Assisted Treatment

PCSS-MAT is comprehensive electronic repository of training materials and educational resources to support evidence-based treatment of opioid use disorder, including courses satisfying the DATA-2000 waiver.

Learn More
DATA 2000-Qualifying Buprenorphine Training

Access 8 hrs of training required for a DEA waiver to prescribe buprenorphine in-office to patients with a substance use disorder.

Learn More
Be Part of the Solution

Join the AMA today and help us lead the effort to reverse the nation’s opioid epidemic.